CAR-T therapy for AML targeting leukemia markers
Part of Blood & lymphatic, Cancer clinical trials.
This early-phase trial tests a personalized immune treatment (CAR-T cells) that targets certain markers found on AML (acute myeloid leukemia) cells. It aims to see if the treatment can help people whose leukemia has specific marker patterns.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 6 months
- Your AML cells show CLL-1, CD123, and/or CD33 on testing (flow cytometry or tissue staining)
- Your overall strength is good (Karnofsky score above 80) and you likely have more than 3 months to live
- Your heart, oxygen level, kidneys, and liver blood tests are within required ranges
- Your blood counts are sufficient (hemoglobin at least 80 g/L)
- You can give written consent (or the legal guardian can, if needed) and the team thinks you can follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a type of immunotherapy called CAR-T cells that are made to target leukemia cells. The cells are designed to attack AML by recognizing several proteins on the cancer cells, and may be an option for patients who have not responded well to other treatments.
This trial tests a lab-made immune cell treatment (CAR T cells) that targets specific markers on acute myeloid leukemia cells. It aims to control the leukemia, but it also involves close monitoring because it is an early-phase study.
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
This trial tests a lab-made immune cell treatment (CAR-T) made to target AML cells with a specific marker (NKG2D ligand). It’s for people whose acute myeloid leukemia (AML) has come back or didn’t respond to standard chemotherapy.
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
This early-phase study tests a customized immune-cell therapy (CAR-T) made from your own T cells to treat acute myeloid leukemia (AML) that has the marker CD123. It may help shrink the leukemia and improve long-term control, but the treatment is still being tested for safety and early effectiveness.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.